On this page
If you take the contraceptive pill
Switch to a non-oral contraceptive method or add a barrier method, such as condoms, for four weeks after starting Mounjaro and four weeks after every dose increase.
Continue taking your pill as prescribed unless a clinician advises you to change it.
Why is extra protection needed?
Mounjaro delays stomach emptying and has been shown to reduce the absorption of oral contraceptive hormones. The effect is most relevant when treatment begins and after the dose increases.
Non-oral methods—including the implant, injection, coil, patch and vaginal ring—are not expected to be affected by Mounjaro in the same way.
Vomiting or diarrhoea
Vomiting soon after taking a contraceptive pill or severe diarrhoea lasting more than 24 hours can also reduce protection. Follow the missed-pill instructions supplied with your pill and use condoms. If vomiting or diarrhoea persists, discuss a non-oral contraceptive method.
If unprotected sex has happened
Seek advice promptly from a pharmacist, GP or sexual-health service about emergency contraception. Tell them you use Mounjaro and which contraception you normally use. A copper intrauterine device is the most effective form of emergency contraception where suitable; the best option needs individual assessment.
Pregnancy and planning a baby
Mounjaro should not be used during pregnancy. If you become pregnant or think you may be pregnant, stop Mounjaro and contact your clinical team promptly.
If you are planning pregnancy, the current recommended washout period is at least one month between stopping tirzepatide and trying to conceive. Arrange a preconception review, particularly if you also have diabetes or take other medicines.
Four things to remember
- Use effective contraception while taking Mounjaro.
- If you use an oral contraceptive, add condoms or change to a non-oral method for four weeks after starting and after every dose increase.
- Follow missed-pill rules after vomiting or severe diarrhoea.
- Do not use Mounjaro during pregnancy.
Official sources
FSRH: GLP-1 agonists and oral contraception
First published July 2026. Last reviewed: 16 July 2026. Planned review: October 2026, or earlier if FSRH or product guidance changes.
Prepared for the Pathfields Healthy Living Portal.